ADmit Therapeutics

ADmit Therapeutics is biotech company focused on the commerzalitation of the MAP-AD Test, the first epigenetic IVD Test for the prognosis of Alzheimer’s disease with the CE IVDR mark. The company has a CAP-accredited and a CLIA-certified laboratory to run the MAP-AD Test as an LDT in the US.